Comparison of Different Treatment Outcomes for Refractory Overactive Bladder: A Systematic Review and Meta-Analysis
Toxins · 26.09.2025 · 17 (10) · 479
DOI: 10.3390/toxins17100479 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Toxins, online erschienen am 26.09.2025. Verfasst von Maria Patricia Roman und 9 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Obstetrics and Gynaecology Clinical Section, Cluj County Emergency Clinical Hospital, 55-57 21st of December 1989 Bld, 400124 Cluj-Napoca, Romani…. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Botulinum Toxins, Type A, Electric Stimulation Therapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Iuliu Haţieganu" University of Medicine and Pharmacy Cluj-Napoca, “Iuliu Haţieganu” University of Medicine and Pharmacy Cluj-Napoca.
Abstract (Originalsprache)
Background
Refractory overactive bladder (OAB) poses a significant clinical burden, often severely impacting quality of life (QoL). While intradetrusor onabotulinumtoxinA (BoNT-A) and sacral neuromodulation (SNM) are established therapeutic options, a direct comparison of their efficacy and safety profiles is essential to guide clinical decision-making. This study compares BoNT-A against placebo and SNM for the management of refractory OAB in women.
Methods
Following PRISMA guidelines, PubMed, Scopus, CENTRAL, and Google Scholar were searched until February 2025 for randomized controlled trials (RCTs) and cohort studies on treatment alternatives for refractory OAB. Treatment outcomes at 3- (BoNT-A vs. placebo) and 6-month (BoNT-A vs. SNM) follow-up were analyzed. Odds ratios (ORs) and mean differences (MDs) were calculated for dichotomous and continuous variables, respectively, with heterogeneity assessed via I2 test. Study quality was evaluated using CASP tools.
Results
Pooled data from 12 studies (2645 patients) indicated that BoNT-A significantly reduced urgency urinary incontinence (UUI) episodes compared to placebo (p = 0.02) and SNM (p = 0.0008). Additionally, a ≥75% reduction in UUI episodes was more likely with BoNT-A compared to both placebo (p < 0.00001) and SNM (p < 0.00001). Complete resolution of UUI was more likely with BoNT-A compared to placebo (p < 0.00001); however, when compared to SNM, the latter demonstrated a higher rate of complete UUI resolution (p < 0.00001). Patient-reported QoL did not show significant differences between BoNT-A and SNM (p = 0.2). Urinary tract infection (UTI) risk was higher with BoNT-A than both comparators.
Conclusions
While BoNT-A offers robust symptom control, its safety profile necessitates careful patient selection. SNM remains a viable alternative for those prioritizing fewer adverse events. The study highlights the need for standardized outcome reporting, long-term cost-effectiveness analyses, and personalized treatment approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 2nd Obstetrics and Gynaecology Clinical Section, Cluj County Emergency Clinical Hospital, 55-57 21st of December 1989 Bld, 400124 Cluj-Napoca, Romania.
- Mother and Child Department, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8 Victor Babes Str, 400347 Cluj-Napoca, Romania.
- Department of Obstetrics and Gynaecology, Epsom and St. Helier University Hospitals NHS Trust, Dorking Rd, Epsom KT187EG, UK.
- Institute of Medical and Biomedical Education, St. George's University of London, Cranmer Terrace, London SW17 0RE, UK.
- Laboratory of Experimental Surgery and Surgical Research "N.S. Christeas", Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Str, Goudi, 11527 Athens, Greece.
- School of Medicine, American University of the Caribbean, Pembroke Pines, FL 33027, USA.
ORCID-Profile: Maria Patricia Roman, Stergios K Doumouchtsis, Viorela Elena Suciu, Ionel Daniel Nati
Förderung
- "Iuliu Haţieganu" University of Medicine and Pharmacy Cluj-Napoca
- “Iuliu Haţieganu” University of Medicine and Pharmacy Cluj-Napoca
Zitieren
APA
Roman, M. P., Ciortea, R., Doumouchtsis, S. K., Măluțan, A. M., Bucuri, C. E., Ormindean, C. M., Suciu, V. E., Nati, I. D., Căilean, A., & Mihu, D. (2025). Comparison of Different Treatment Outcomes for Refractory Overactive Bladder: A Systematic Review and Meta-Analysis. Toxins, 17(10), 479. https://doi.org/10.3390/toxins17100479
Vancouver
Roman MP, Ciortea R, Doumouchtsis SK, Măluțan AM, Bucuri CE, Ormindean CM, et al. Comparison of Different Treatment Outcomes for Refractory Overactive Bladder: A Systematic Review and Meta-Analysis. Toxins. 2025;17(10):479. doi:10.3390/toxins17100479
BibTeX
@article{Roman2025,
author = {Roman, Maria Patricia and Ciortea, Răzvan and Doumouchtsis, Stergios K and Măluțan, Andrei Mihai and Bucuri, Carmen Elena and Ormindean, Cristina Mihaela and Suciu, Viorela Elena and Nati, Ionel Daniel and Căilean, Andreea and Mihu, Dan},
title = {Comparison of Different Treatment Outcomes for Refractory Overactive Bladder: A Systematic Review and Meta-Analysis},
journal = {Toxins},
year = {2025},
volume = {17},
number = {10},
pages = {479},
doi = {10.3390/toxins17100479}
}
EUVIMED